SBIR Phase I: Physiologic High Throughput Screening of Bioengineered Tissues

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$99,991.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
0610721
Agency Tracking Number:
0610721
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Myomics
4 Richmond Square, Suite 500, Providence, RI, 02906
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Herman Vandenburgh
Dr
(401) 861-9770
hvandenburgh@myomics.com
Business Contact:
Victoria Barbata
(401) 861-9770
vbarbata@myomics.com
Research Institution:
n/a
Abstract
The Small Business Innovation Research (SBIR) Phase I project will develop an innovative high-throughput/ high content drug screening platform utilizing three-dimensional human skeletal muscle tissue constructs which mimic in vivo skeletal muscle to quantify muscle force generation. The proposed drug testing platform will contribute to significant reductions in time and costs associated with bringing new drugs to market by discovering drug candidates and eliminating ineffective compounds earlier than currently possible. Converging biological systems (in vitro human muscle analogs) with optomechanics (sensors capable of monitoring muscle contractility) enables a novel and powerful drug testing platform. Unlike existing systems, this research incorporates biomechanics into drug discovery by using mechanical sensors to detect contraction of multiple identical tissue samples over extended time periods. This interdisciplinary approach employs mechanical/electrical engineering and biological aspects, providing an early means of separating prospective muscle drug candidates from those likely to fail in humans. This research will impact muscle contractility disorder/disease research, the pharmaceutical industry, and the biotechnology industry. Significant demands exist for new drugs treating contractility disorders involving skeletal muscle. Significant socioeconomic and quality-of-life impacts will result for patients with contractility disorders, i.e., sarcopenia, atrophy or Duchennes muscular dystrophy. Upon successful development, the sensing mechanism will potentially be used to test several contractile tissues relevant to a range of important human contractile disorders and diseases.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government